Current treatments
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Moreau P et al. Blood. 2016 Mar 21. pii: blood-2016-01-693580. [Epub ahead of print]. Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib? Gozzetti A et al. Br…
Details